Prostate cancer

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More